Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

Published:2019-11-28 Issue:6 Volume:79 Page:590-603
ISSN:0340-1855
Container-title:Zeitschrift für Rheumatologie
language:en
Short-container-title:Z Rheumatol

Author:

Lee Y. H.,Song G. G.

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s00393-019-00733-x.pdf

Reference38 articles.

1. Aletaha D, Landewe R, Karonitsch T et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Care Res 59(10):1371–1377

2. Brown S, Hutton B, Clifford T et al (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. Syst Rev 3(1):110

3. Burmester GR, Benda B, Gruben D et al (2013) Tofacitinib for rheumatoid arthritis—authors’ reply. Lancet 381(9880):1812–1813

4. Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897

5. Changelian PS, Flanagan ME, Ball DJ et al (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302(5646):875–878

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs;Current Medicinal Chemistry;2022-09

2. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy;Rheumatology;2022-05-17

3. Filgotinib in Rheumatoid Arthritis: A Profile of Its Use;Clinical Drug Investigation;2021-07-25

4. Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis;Medicine;2021-07-23

5. Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis;Expert Opinion on Emerging Drugs;2021-07-03